Digital Diagnostics is a pioneering autonomous AI diagnostics company on a mission to transform the quality, accessibility, equity, and affordability of global healthcare through the application of technology in the medical diagnosis and treatment process. Digital Diagnostics’ flagship product, IDx-DR, detects diabetic retinopathy (including macular edema) at point-of-care to provide the patient with a diagnostic report without a physician evaluation. After completing a rigorous prospective, preregistered clinical trial at primary care sites across the country, IDx-DR became the first and only FDA De Novo-cleared AI diagnostic system to make a diagnosis without physician input. IDx-DR is deployed in point-of-care offices across the United States and Europe. The company is paving the way for autonomous AI diagnosis to become a standard of care by working with patient advocacy groups, federal regulators, and other quality of care and ethics-focused stakeholders.